TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07733947: A Phase 3b, Multicenter, Two Stage, Double-blind, Long Term Follow up and Open Label Extension Study of Participants Who Have Completed the CBL-0301 or CBL-0302 Study for Reducing Abdominal Subcutaneous Fat (Stage 1)

Sponsor: Caliway Biopharmaceuticals Co., Ltd. · Phase: PHASE3 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 300 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$15,086,080

Rescue Site Savings

+$9,947,384

Unlock Full NCT07733947 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07733947 Rescue Dossier →